Bioimpedance Analyzers Market Report 2025

This Bioimpedance Analyzers market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The bioimpedance analyzers market size has grown rapidly in recent years. It will grow from $0.59 billion in 2024 to $0.67 billion in 2025 at a compound annual growth rate (CAGR) of 14.5%. The growth in the historic period can be attributed to the growing obesity epidemic, changing lifestyles and an increase in home delivery, rising prevalence of blood disorders such as anemia, and leukemia, prevalence of chronic diseases, and growing geriatric population.

The bioimpedance analyzers market size is expected to see rapid growth in the next few years. It will grow to $1.14 billion in 2029 at a compound annual growth rate (CAGR) of 14.1%. The growth in the forecast period can be attributed to growth in healthcare infrastructure, increasing funding and initiatives, increasing health awareness, growing spending on healthcare services, and rising consumption of junk foods. Major trends in the forecast period include technological advancements, personalized healthcare solutions, adoption of telehealth services, non-invasive technologies, and integration with wearable technology.

The growing concerns over obesity are anticipated to drive the expansion of the bioimpedance analyzers market. Obesity, characterized by an excessive accumulation of body fat that adversely affects health, is increasingly prevalent due to the widespread availability of high-calorie, high-fat, and high-sugar foods, along with sedentary lifestyles and decreased physical activity. Bioimpedance analyzers play a crucial role in managing obesity by providing detailed and actionable data on body composition. This information supports personalized treatment plans, monitors health risks, motivates patients, assesses fluid balance, improves clinical outcomes, and enhances research efforts. For instance, in March 2023, the World Heart Foundation, a Switzerland-based cardiovascular community organization, reported that approximately 2.3 billion adults and children globally are obese or overweight. If current trends continue, this number is projected to reach 2.7 billion by 2025. Consequently, increasing concerns about obesity are fueling growth in the bioimpedance analyzers market.

Leading companies in the bioimpedance analyzer market are focusing on developing advanced products, such as body composition scales, to provide more accurate health assessments and enhance user convenience. A body composition scale uses bioimpedance analysis (BIA) to estimate various components of body composition, offering insights beyond simple body weight. For example, in September 2022, Xiaomi, a China-based electronics company, introduced its eight-electrode body composition scale. This innovative scale employs dual-frequency bioimpedance measurement technology, enabling it to deliver up to 35 body composition reports with greater accuracy compared to traditional single-frequency scales. The scale utilizes multi-frequency biological alternating current to accurately measure body fat, water, muscle, and other body indices.

In June 2022, PharmaNutra S.p.A., an Italy-based nutritional company, acquired Akern S.r.l. for an undisclosed amount. This acquisition allows PharmaNutra to leverage Akern’s established research and development capabilities and distribution network, thereby diversifying its business operations and enhancing its competitiveness in the nutritional supplement and medical device markets. Akern, based in Italy, specializes in manufacturing bioimpedance analyzers.

Major companies operating in the bioimpedance analyzers market are Xiaomi Corporation, Omron Corporation, Beurer GmbH, InBody Co Ltd., Seca GmbH & Co., Withings, Lumsail Industrial Inc., Zurich Instruments Ltd., RJL Systems Inc., ImpediMed Limited, Biodynamics Corporation, Charder Electronic Co Ltd., Akern Srl, Bioparhom, BioTekna Limited, Bodystat Ltd., EVOLT 360 Limited, Maltron International Ltd., Tanita Corporation, Tongfang Health Technology (Beijing) Co.Ltd.

North America was the largest region in the bioimpedance analyzer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioimpedance analyzers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioimpedance analyzers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Bioimpedance analyzers are devices designed to measure the electrical impedance of biological tissues, primarily for assessing body composition. They operate by passing a small, safe electrical current through the body and measuring how the current's flow is impeded, which varies with different types of tissues.

The primary types of bioimpedance analyzers are multi-frequency, single-frequency, and dual-frequency. Multi-frequency analyzers use various frequencies of electrical current to assess body composition. The available modalities include wired and wireless bioimpedance. These analyzers are applied in whole-body and segmental body measurements, and are used by hospitals, fitness clubs, wellness centers, home users, and others.

The bioimpedance analyzers market research report is one of a series of new reports that provides bioimpedance analyzers market statistics, including bioimpedance analyzers industry global market size, regional shares, competitors with a bioimpedance analyzers market share, detailed bioimpedance analyzers market segments, market trends, and opportunities, and any further data you may need to thrive in the bioimpedance analyzers industry. This bioimpedance analyzer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bioimpedance analyzers market consists of sales of bioimpedance spectroscopy, segmental bioimpedance analyzers, handheld bioimpedance analyzers, and clinical-grade bioimpedance analyzers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.